Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 0.41 |
| ▸ | HTR2B | P41595 | 19/20 | 0.41 |
| ▸ | HTR2A | P28223 | 18/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943826 | 1.00 | HTR2C (0.41) | HTR2CHTR2BHTR2A | |
| SCHEMBL995419 | 1.00 | HTR2C (0.41) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL1990850 | 0.98 | HTR2C (0.40) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL15240232 | 0.98 | HTR2C (0.40) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL18149760 | 0.98 | HTR2C (0.40) | HTR2CHTR2BHTR2A | |
| SCHEMBL17062759 | 0.81 | HTR2C (0.41) | HTR2CHTR2BHTR2A | |
| SCHEMBL21201838 | 0.74 | NAAA (0.37) | HTR2CHTR2BHTR2A | |
| SCHEMBL3762022 | 0.74 | HTR2C (0.39) | HTR2CHTR2BHTR2A | |
| SCHEMBL1254583 | 0.74 | HTR2C (0.39) | HTR2CHTR2BHTR2A | |
| SCHEMBL994956 | 0.74 | HTR2C (0.39) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| CN-119654321-A | PI3K alpha inhibitors | 突触活化疗法股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| WO-2024013209-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-01-18 | — | — | WO | claimed |
| EP-3911648-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | claimed |
| CN-113574055-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2021-10-29 | — | — | CN | claimed |
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| CN-113412258-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2021-09-17 | — | — | CN | claimed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | claimed |
| EP-2751104-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | claimed |
| EP-3489238-A1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | Dart NeuroScience (Cayman) Ltd (KY) | 2019-05-29 | — | — | EP | claimed |
| US-20150051206-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2015-02-19 | — | — | US | claimed |
| US-20140228347-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-08-14 | — | — | US | claimed |
| EP-2751105-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | claimed |
| EP-2751104-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | claimed |
| US-8754071-B2 | Compounds and compositions as c-kit kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-06-17 | — | — | US | claimed |
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-01-30 | — | — | US | claimed |
| US-8569283-B2 | Compounds and compositions as c-Kit kinase inhibitors | IRM LLC (BM) | 2013-10-29 | — | — | US | claimed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | claimed |
| WO-2013033167-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | claimed |
| WO-2013033203-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051206-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | HTR2C 2465/4885HTR2B 2374/4885HTR2A 1971/4885 |
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | HTR2C 2465/4885HTR2B 2374/4885HTR2A 1971/4885 |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | HTR2C 2465/4885HTR2B 2374/4885HTR2A 1971/4885 |
| US-20140228347-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | HTR2C 2465/4885HTR2B 2374/4885HTR2A 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.